SMYD2
N-lysine methyltransferase SMYD2
Protein Summary
Protein-lysine N-methyltransferase that methylates both histones and non-histone proteins, including p53/TP53 and RB1. Specifically methylates histone H3 'Lys-4' (H3K4me) and dimethylates histone H3 'Lys-36' (H3K36me2). Shows even higher methyltransferase activity on p53/TP53. Monomethylates 'Lys-370' of p53/TP53, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity of p53/TP53. Monomethylates RB1 at 'Lys-860'. SET domain-containing proteins, such as SMYD2, catalyze lysine methylation (Brown et al., 2006 [PubMed 16805913]).[supplied by OMIM, Nov 2008]
- ENST00000366957
- ENSP00000355924
- ENSG00000143499
- KMT3C
- KMT3C
- HSKM-B
- ZMYND14
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
molecular function | 0.88 | ||
disease perturbation | 0.87 | ||
histone modification site profile | 0.87 | ||
transcription factor perturbation | 0.84 | ||
kinase perturbation | 0.81 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 85.88 (req: < 5)
Gene RIFs: 57 (req: <= 3)
Antibodies: 305 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 85.88 (req: >= 5)
Gene RIFs: 57 (req: > 3)
Antibodies: 305 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 14
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 55
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0